Autologous transplantation and maintenance therapy in multiple myeloma.

@article{Palumbo2014AutologousTA,
  title={Autologous transplantation and maintenance therapy in multiple myeloma.},
  author={Antonio Palumbo and Federica Cavallo and Francesca Gay and Francesco Di Raimondo and Dina Ben Yehuda and Maria Teresa Petrucci and Sara Pezzatti and Tommaso Caravita and Chiara Cerrato and Elena Ribakovsky and Mariella Genuardi and Anna Maria Cafro and Magda Marcatti and Lucio Catalano and Massimo Offidani and Angelo Michele Carella and Elena Zamagni and Francesca Patriarca and Pellegrino Musto and Andrea Evangelista and Giovannino Ciccone and Paola Omedé and Claudia Crippa and Paolo Corradini and Arnon Nagler and Mario Boccadoro and Michele Cavo},
  journal={The New England journal of medicine},
  year={2014},
  volume={371 10},
  pages={
          895-905
        }
}
BACKGROUND This open-label, randomized, phase 3 study compared melphalan at a dose of 200 mg per square meter of body-surface area plus autologous stem-cell transplantation with melphalan-prednisone-lenalidomide (MPR) and compared lenalidomide maintenance therapy with no maintenance therapy in patients with newly diagnosed multiple myeloma. METHODS We randomly assigned 273 patients 65 years of age or younger to high-dose melphalan plus stem-cell transplantation or MPR consolidation therapy… Expand
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
TLDR
Among adults with multiple myeloma, RVD therapy plus transplantation was associated with significantly longer progression‐free survival than RVD Therapy alone, but overall survival did not differ significantly between the two approaches. Expand
Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
TLDR
LenMT dose correlated with efficacy and toxicity; high rates of dose reductions during CT argue against a high starting dose, however, continuous up- and down-titration for each patient to the current maximum tolerated dose is prudent. Expand
Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial
TLDR
Based on hazard ratio, the short treatment arm consisting of mobilization chemotherapy and tandem MEL140 achieved 96% of the progression-free survival, demonstrating its value as an independent component of therapy in older patients with multiple myeloma who are considered fit for autologous transplantation. Expand
LENALIDOMIDE AND VORINOSTAT MAINTENANCE AFTER AUTOLOGOUS TRANSPLANT IN MULTIPLE MYELOMA-LONG TERM FOLLOW-UP.
  • Nidhi Sharma, David T Chen, +10 authors Y. Efebera
  • Medicine
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2019
TLDR
The combination of vorinostat and lenalidomide as maintenance post ASCT is tolerable and induces durable response, and a phase III randomized study of lenalidumide vs. combination with vorInostat is warranted. Expand
RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group
TLDR
The outcome was promising, but high-risk patients need more effective treatment approach, and flow-negativity with the conventional flow was an independent predictor for longer PFS. Expand
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial
TLDR
The optimal way to use immunomodulatory drugs as components of induction and maintenance therapy for multiple myeloma is unresolved and results favored CRD over CTD across all subgroups, including patients with International Staging System stage III disease. Expand
A pilot study of lenalidomide maintenance therapy after autologous transplantation in relapsed or refractory classical Hodgkin lymphoma.
  • Lauren K. Shea, M. Watkins, +9 authors T. Fehniger
  • Medicine
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2020
TLDR
It is concluded that the regimen of maintenance lenalidomide explored in this study is not feasible for cHL patients immediately following ASCT, and an alternative lenalidOMide dose or schedule may be better tolerated following AsCT for patients with rel/ref cHL. Expand
Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma.
TLDR
Results indicate that maintenance therapy with bortezomib represents a safe, well-tolerated, and efficacious option for patients with high-risk cytogenetics, renal insufficiency, an inability to tolerate lenalidomide, or a previous history of another cancer. Expand
Multiple myeloma: new treatments gain momentum
TLDR
It is shown that VRd was better than Rd in terms of progression-free survival in diff erent age categories, namely in those younger than 65 years, those aged between 65 and 75 years, and even in the 11% of patients older than75 years, which should receive an additional substantial boost by combining such regimens with daratumumab. Expand
From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
TLDR
The addition of high-dose melphalan followed by autologous transplantation significantly improves progression-free survival, although an overall survival benefit was not observed in all trials. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 28 REFERENCES
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
TLDR
Lenalidomide maintenance after transplantation significantly prolonged progression-free and event-free survival among patients with multiple myeloma. Expand
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
TLDR
High-dose therapy with autologous stem-cell rescue is an effective first-line treatment for patients with multiple myeloma who are younger than 65 years of age and trend toward a greater survival benefit in the group of patients with a poor prognosis. Expand
Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
TLDR
MPR-R significantly prolonged progression-free survival in patients with newly diagnosed multiple myeloma who were ineligible for transplantation, with the greatest benefit observed in patients 65 to 75 years of age. Expand
IMWG consensus on maintenance therapy in multiple myeloma.
TLDR
Thalidomide maintenance therapy after autologous stem cell transplantation improved the quality of response and increased progression-free survival significantly in all 6 studies and overall survival in 3 of them and in elderly patients, 2 trials showed a significant prolongation of PFS, but no improvement in OS. Expand
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
TLDR
The response rate among the patients who received high-dose therapy was 81 percent, whereas it was 57 percent in the group treated with conventional chemotherapy (P<0.001). Expand
Lenalidomide after stem-cell transplantation for multiple myeloma.
TLDR
Lenalidomide maintenance therapy, initiated at day 100 after hematopoietic stem-cell transplantation, was associated with more toxicity and second cancers but a significantly longer time to disease progression and significantly improved overall survival among patients with myeloma. Expand
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
TLDR
Bortezomib during induction and maintenance improves CR and achieves superior PFS and OS and a benefit was also observed in patients with deletion 17p13. Expand
Update on the initial therapy of multiple myeloma.
  • D. Reece
  • Medicine
  • American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
  • 2013
TLDR
Improvements in dosing have decreased the toxicity of these regimens, and better methods of risk stratification and the availability of even newer drugs will allow future refinements in myeloma treatment. Expand
Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma
TLDR
It is shown that an improvement in OS after HDC/SCT may be related to induction therapy with novel agents as opposed to chemotherapy, and the data extrapolate on prior work and expand on ongoing controversies about optimal induction regimens for patients with MM. Expand
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial
TLDR
Oral MPT is an effective first-line treatment for elderly patients with multiple myeloma and anticoagulant prophylaxis reduces frequency of thrombosis. Expand
...
1
2
3
...